Alkermes After Elan: A Slow Start But A Maturing Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
As it continues its transformation into a drug development company, Alkermes says it is meeting its own expectations, but analysts are disappointed, at least in the short term.